{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:17:32Z","timestamp":1787872652063,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06213-6","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:08:49Z","timestamp":1781777329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain metastatic paraganglioma from liver: a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"given":"Hongwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuandong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"3","key":"6213_CR1","first-page":"271","volume":"54","author":"N Aygun","year":"2020","unstructured":"Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Clinical Findings to Diagnosis. Sisli Etfal Hastan Tip Bul. 2020;54(3):271\u201380.","journal-title":"Sisli Etfal Hastan Tip Bul"},{"issue":"12","key":"6213_CR2","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1245\/s10434-017-6074-1","volume":"24","author":"M Dhir","year":"2017","unstructured":"Dhir M, Li W, Hogg ME, Bartlett DL, Carty SE, McCoy KL, Challinor SM, Yip L. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2017;24(12):3624\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"6213_CR3","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6213_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","volume":"33","author":"DJ Pinato","year":"2016","unstructured":"Pinato DJ, Black JR, Ramaswami R, Tan TM, Adjogatse D, Sharma R. Peptide receptor radionuclide therapy for metastatic paragangliomas. Med Oncol. 2016;33(5):47.","journal-title":"Med Oncol"},{"issue":"11","key":"6213_CR5","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012;118(11):2804\u201312.","journal-title":"Cancer"},{"issue":"9","key":"6213_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/ERC-21-0392","volume":"29","author":"K Perez","year":"2022","unstructured":"Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, Alexander H, Baddoo W, Astone K, Esplin ED, et al. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022;29(9):533\u201344.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"6213_CR7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, D\u00e9andreis D, Borget I, Loriot C, Chougnet C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711\u201320.","journal-title":"Int J Cancer"},{"issue":"12","key":"6213_CR8","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1007\/s40618-024-02398-z","volume":"47","author":"Y Cui","year":"2024","unstructured":"Cui Y, Gao Y, Zhou Y, Ma X, Wang Y, Zhou T, Wen J, Chen S, Lu L, Tong A, et al. A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas. J Endocrinol Invest. 2024;47(12):3039\u201348.","journal-title":"J Endocrinol Invest"},{"key":"6213_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fendo.2020.00061","volume":"11","author":"A Tong","year":"2020","unstructured":"Tong A, Li M, Cui Y, Ma X, Wang H, Li Y. Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature. Front Endocrinol (Lausanne). 2020;11:61.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6213_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7326\/0003-4819-123-2-199507150-00004","volume":"123","author":"JW Lenders","year":"1995","unstructured":"Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123(2):101\u20139.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"6213_CR11","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.33549\/physiolres.931502","volume":"57","author":"R B\u00edlek","year":"2008","unstructured":"B\u00edlek R, \u0160afa\u0159\u00edk L, Ciprov\u00e1 V, Vlcek P, Lis\u00e1 L. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res. 2008;57(Suppl 1):S171-s179.","journal-title":"Physiol Res"},{"key":"6213_CR12","doi-asserted-by":"crossref","unstructured":"B\u00edlek R, Vl\u010dek P, \u0160afa\u0159\u00edk L, Michalsk\u00fd D, Nov\u00e1k K, Du\u0161kov\u00e1 J, V\u00e1clav\u00edkov\u00e1 E, Widimsk\u00fd J, Jr., Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel). 2019; 11(4).","DOI":"10.3390\/cancers11040586"},{"issue":"6","key":"6213_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","volume":"474","author":"C Pierre","year":"2019","unstructured":"Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, Nomine C, Lomazzi S, Vignaud JM, Weryha G, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch. 2019;474(6):721\u201334.","journal-title":"Virchows Arch"},{"issue":"2","key":"6213_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181\u201393.","journal-title":"Cancer Cell"},{"issue":"6","key":"6213_CR15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"6213_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574662","volume":"11","author":"X Ma","year":"2020","unstructured":"Ma X, Li M, Tong A, Wang F, Cui Y, Zhang X, Zhang Y, Chen S, Li Y. Genetic and clinical profiles of pheochromocytoma and paraganglioma: a single center study. Front Endocrinol (Lausanne). 2020;11: 574662.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6213_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101\u201311.","journal-title":"Nat Rev Endocrinol"},{"key":"6213_CR18","doi-asserted-by":"crossref","unstructured":"Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y, Yonese J, Inamura K, Takahashi S. Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma\/paraganglioma. Virchows Arch 2024.","DOI":"10.1007\/s00428-024-04009-x"},{"issue":"5454","key":"6213_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.287.5454.848","volume":"287","author":"BE Baysal","year":"2000","unstructured":"Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848\u201351.","journal-title":"Science"},{"issue":"8","key":"6213_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/gim.2014.162","volume":"17","author":"L Evenepoel","year":"2015","unstructured":"Evenepoel L, Papathomas TG, Krol N, Korpershoek E, de Krijger RR, Persu A, Dinjens WN. Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med. 2015;17(8):610\u201320.","journal-title":"Genet Med"},{"issue":"11","key":"6213_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jmg.2008.058560","volume":"45","author":"BE Baysal","year":"2008","unstructured":"Baysal BE. Clinical and molecular progress in hereditary paraganglioma. J Med Genet. 2008;45(11):689\u201394.","journal-title":"J Med Genet"},{"issue":"5","key":"6213_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"5","key":"6213_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bbabio.2012.09.009","volume":"1827","author":"S Grimm","year":"2013","unstructured":"Grimm S. Respiratory chain complex II as general sensor for apoptosis. Biochim Biophys Acta. 2013;1827(5):565\u201372.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"6213_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jmedgenet-2020-107656","volume":"60","author":"JP Bayley","year":"2023","unstructured":"Bayley JP, Bausch B, Jansen JC, Hensen EF, van der Tuin K, Corssmit EP, Devilee P, Neumann HP. SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma. J Med Genet. 2023;60(1):25\u201332.","journal-title":"J Med Genet"},{"issue":"5","key":"6213_CR25","doi-asserted-by":"publisher","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","volume":"107","author":"DF Davidoff","year":"2022","unstructured":"Davidoff DF, Benn DE, Field M, Crook A, Robinson BG, Tucker K, De Abreu LR, Burgess JR, Clifton-Bligh RJ. Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study. J Clin Endocrinol Metab. 2022;107(5):e1907\u201316.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6213_CR26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1101\/gad.1385806","volume":"20","author":"J Sierra","year":"2006","unstructured":"Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev. 2006;20(5):586\u2013600.","journal-title":"Genes Dev"},{"key":"6213_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101778","volume":"37","author":"Z Chen","year":"2023","unstructured":"Chen Z, Qi Y, Shen J, Chen Z. Histone demethylase KDM6A coordinating with KMT2B regulates self-renewal and chemoresistance of non-small cell lung cancer stem cells. Transl Oncol. 2023;37: 101778.","journal-title":"Transl Oncol"},{"issue":"10","key":"6213_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.str.2020.07.002","volume":"28","author":"Y Li","year":"2020","unstructured":"Li Y, Zhao L, Tian X, Peng C, Gong F, Chen Y. Crystal Structure of MLL2 Complex Guides the Identification of a Methylation Site on P53 Catalyzed by KMT2 Family Methyltransferases. Structure. 2020;28(10):1141-1148.e1144.","journal-title":"Structure"},{"issue":"11","key":"6213_CR29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"10167","key":"6213_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367.","journal-title":"Lancet"},{"issue":"22","key":"6213_CR31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","volume":"128","author":"CH Moskowitz","year":"2016","unstructured":"Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, et al. Pembrolizumab in relapsed\/refractory classical hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 study. Blood. 2016;128(22):1107.","journal-title":"Blood"},{"issue":"5","key":"6213_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5): e180013.","journal-title":"JAMA Oncol"},{"issue":"11","key":"6213_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"6213_CR34","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1210\/jc.2004-2025","volume":"90","author":"G Eisenhofer","year":"2005","unstructured":"Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, Adams KT, Pacak. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab. 2005;90(4):2068\u201375.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6213_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1210\/jcem-61-4-769","volume":"61","author":"JF Chatal","year":"1985","unstructured":"Chatal JF, Charbonnel. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab. 1985;61(4):769\u201372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6213_CR36","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1210\/jc.2012-2975","volume":"98","author":"AP Gimenez-Roqueplo","year":"2013","unstructured":"Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013;98(1):E162-173.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6213_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","volume":"104","author":"HJ Timmers","year":"2012","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams, Timmers HJLM, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6213_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg. 2018;268(1):172\u20138.","journal-title":"Ann Surg"},{"issue":"2","key":"6213_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M. Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Horm Cancer. 2017;8(2):108\u201318.","journal-title":"Horm Cancer"},{"issue":"10","key":"6213_CR40","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","volume":"47","author":"PM Patel","year":"2011","unstructured":"Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476\u201383.","journal-title":"Eur J Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06213-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:31:47Z","timestamp":1787869907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06213-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6213"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06213-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the First Affiliated Hospital of USTC (2024-RE-475), Hefei, China, and was conducted in full compliance with all principles of the Helsinki Declaration.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"505"}}